Roth Mkm Lowers CervoMed (NASDAQ:CRVO) Price Target to $11.00

CervoMed (NASDAQ:CRVO) had its price objective reduced by analysts at Roth Mkm from $19.00 to $11.00 in a report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Roth Mkm’s target price would indicate a potential upside of 160.05% from the company’s previous close.

A number of other equities analysts have also recently issued reports on the stock. Zacks Research raised shares of CervoMed from a “strong sell” rating to a “hold” rating in a research note on Monday, January 12th. D. Boral Capital reiterated a “buy” rating and set a $31.00 target price on shares of CervoMed in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of CervoMed in a research note on Wednesday, January 21st. HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of CervoMed in a research report on Thursday, December 18th. Finally, raised CervoMed to a “strong-buy” rating in a research note on Tuesday, February 3rd. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, CervoMed currently has an average rating of “Moderate Buy” and an average target price of $23.00.

CervoMed Trading Down 0.2%

CervoMed stock opened at $4.23 on Wednesday. The company has a market cap of $39.17 million, a PE ratio of -1.42 and a beta of -0.77. CervoMed has a 1 year low of $3.58 and a 1 year high of $16.94. The company’s 50-day moving average is $5.21 and its two-hundred day moving average is $7.19.

CervoMed (NASDAQ:CRVO) last issued its quarterly earnings results on Friday, March 13th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.09). The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.84 million. CervoMed had a negative return on equity of 96.04% and a negative net margin of 672.80%. Research analysts forecast that CervoMed will post -1.88 EPS for the current year.

Institutional Investors Weigh In On CervoMed

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of CervoMed by 1.0% during the third quarter. Vanguard Group Inc. now owns 343,463 shares of the company’s stock worth $2,779,000 after purchasing an additional 3,445 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of CervoMed by 8,425,900.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 84,260 shares of the company’s stock valued at $666,000 after buying an additional 84,259 shares during the period. Jane Street Group LLC bought a new stake in shares of CervoMed in the 2nd quarter valued at $414,000. Citizens Financial Group Inc. RI increased its position in shares of CervoMed by 23.0% in the 4th quarter. Citizens Financial Group Inc. RI now owns 37,477 shares of the company’s stock valued at $296,000 after buying an additional 7,000 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in CervoMed during the 3rd quarter worth $247,000. 25.15% of the stock is currently owned by institutional investors and hedge funds.

CervoMed News Summary

Here are the key news stories impacting CervoMed this week:

• Positive Sentiment: New clinical data presented at the AD/PD 2026 conference show that neflamapimod produced greater benefit in Dementia with Lewy Bodies (DLB) patients who have low plasma pTau181 (i.e., likely without Alzheimer’s co‑pathology). This can increase the perceived commercial and regulatory value of the program for a clearer DLB target population. GlobeNewswire: AD/PD 2026 Data
• Positive Sentiment: HC Wainwright reiterated a Buy and a $25 price target while trimming some near-term EPS forecasts but raising several quarterly and FY2026/FY2027 estimates overall (and raising some quarter estimates). The firm’s maintained Buy and higher longer‑term estimates support upside expectations. MarketBeat: HC Wainwright Notes
• Positive Sentiment: Chardan Capital raised its price target from $15 to $21 and kept a Buy rating, signaling investor conviction from another boutique healthcare analyst. TickerReport: Chardan Raise
• Positive Sentiment: D. Boral Capital published a Buy rating on CRVO, adding to the list of brokers expressing conviction in the story. American Banking News: Buy Rating
• Neutral Sentiment: Coverage notes and press summaries report the company was “flat” on Q4/FY results; no new material guidance or financing announcements were reported in those summaries. Market reaction may therefore hinge on interpretation of pipeline updates and analyst notes. BayStreet: Flat on Q4/FY
• Neutral Sentiment: Reported short‑interest data for March are effectively meaningless in the published entry (shows 0 shares / NaN change), so short‑squeeze or added short pressure is not an active driver based on that report.
• Negative Sentiment: Roth MKM lowered its price target from $19 to $11 (while still on Buy), which reduces near‑term analyst upside and could pressure sentiment among investors focused on published targets. Benzinga: Roth MKM PT Cut
• Negative Sentiment: HC Wainwright trimmed its Q1 2026 EPS estimate (worse near‑term quarterly view), underscoring continued execution and cash‑burn risk until definitive late‑stage data or partnering/financing alleviates funding concerns.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.